Comparative analysis of DOAC reversal agents in patients with intracranial hemorrhage for preventing bleed expansion after neurosurgical intervention: andexanet alfa vs. 4-factor PCC
Publication/Presentation Date
7-2025
Volume
17
First Page
100
Last Page
101
Published In/Presented At
Rao A, Hannah T, Pathak S, et al E-013 Comparative analysis of DOAC reversal agents in patients with intracranial hemorrhage for preventing bleed expansion after neurosurgical intervention: andexanet alfa vs. 4-factor PCC Journal of NeuroInterventional Surgery 2025;17:A100-A101.
Disciplines
Medicine and Health Sciences
Department(s)
Fellows and Residents
Document Type
Article
COinS